Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$3.14
-2.2%
$2.98
$2.07
$4.20
$101.14M0.39104,481 shs65,863 shs
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.10
+6.9%
$5.45
$2.81
$485.37
$2.36M5.58606,935 shs209,376 shs
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$15.09
-1.3%
$0.00
$11.06
$63.00
$295.01M1.5224,533 shs114,029 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.63
-0.6%
$1.67
$1.15
$3.50
$11.40M-0.3422,799 shs5,823 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-4.18%-2.73%+16.30%+34.87%+40.17%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-3.97%-4.92%-41.41%-85.64%-99.96%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-3.78%-5.27%-98.01%-98.01%-98.01%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-3.53%-4.65%-10.33%+23.31%-47.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.6535 of 5 stars
3.63.00.00.01.13.30.0
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
2.1053 of 5 stars
3.53.00.00.00.60.01.3
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.3037 of 5 stars
3.80.00.03.72.51.70.6
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
3.9443 of 5 stars
3.04.00.04.60.90.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00
N/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00186.62% Upside
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.007,065,706.45% Upside
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0065.67% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00206.75% Upside

Current Analyst Ratings Breakdown

Latest NERV, APVO, ADMS, CBIO, and ANIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
6/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
4/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$210K481.62N/AN/A$0.59 per share5.32
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.76N/AN/A$65.21 per share0.05
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K29,500.95N/AN/A$8.24 per share1.83
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share7.90($3.67) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.38N/AN/AN/A-68.17%-60.38%9/5/2025 (Estimated)
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.821.99N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)

Latest NERV, APVO, ADMS, CBIO, and ANIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
6/3/2025Q2 2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.10-$0.09+$0.01-$0.09N/AN/A
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
8.89
8.89
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
0.67
0.67
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
532.21 million24.06 millionOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50760,000755,000Not Optionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million17.85 millionNo Data
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 millionN/ANot Optionable

Recent News About These Companies

Minerva nights event to include music, food, games
Minerva Neurosciences Inc.
Minerva Neurosciences regains Nasdaq compliance
Minerva chamber member honored as 'Bright Star'

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamas Pharmaceuticals stock logo

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$3.14 -0.07 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$3.22 +0.07 (+2.39%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$3.10 +0.20 (+6.90%)
Closing price 04:00 PM Eastern
Extended Trading
$3.03 -0.07 (-2.26%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$15.09 -0.20 (-1.31%)
As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.63 -0.01 (-0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.67 +0.04 (+2.45%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.